This Primary Biliary Cholangitis Market report provides key statistics on the market status of Global and Regional manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. The report reveals the nature of demand for the firm’s product to know if the demand for the product is constant or seasonal. With this report not only an unskilful individual but also a professional can easily extrapolate the entire market within a few seconds. TOC, graphs and tables included in the report helps understand the market size, share, trends, growth drivers and market opportunities and challenges.
 
Data Bridge Market Research analyses that the primary biliary cholangitis market was valued at USD 784.81 million in 2021 and is expected to reach USD 1,744.47 million by 2029, registering a CAGR of 10.50% during the forecast period of 2022 to 2029.
 
Download Sample PDF Copy of this Report to understand structure of the complete report (Including Full TOC, Table & Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-primary-biliary-cholangitis-market
 
Market Overview:
 
Primary biliary cholangitis, also known as primary biliary cirrhosis, is a chronic liver condition in which the bile ducts are gradually damaged. PBC has no known treatment. To control symptoms and reduce the progression of PBC, doctors prescribe medication. Ursodiol aids in the removal of bile from the liver. In many cases, this medication improves liver function and slows the course of liver disease. If ursodeoxycholic acid (UDCA) is ineffective or cannot be tolerated, obeticholic acid is used alone or in combination with it. This treatment lowers bile production while increasing bile flow out of the liver. Other pharmacological choices are available depending on the individual circumstances of each patient and the existence of other medical disorders. If liver function continues to deteriorate after medical treatment, a liver transplant may be required.
 
Primary biliary cirrhosis is a chronic liver disease that produces inflammation, fibrosis, and bile duct obstruction, resulting in the loss of tiny bile ducts within the liver. Autoimmunity, infection, and/or genetic predisposition are all possible causes of primary biliary cirrhosis. Itching, osteoporosis, high blood cholesterol, and malabsorption of fat and fat-soluble vitamins are symptoms of primary biliary cirrhosis, which can progress to hepatomegaly and hyperpigmentation splenomegaly, jaundice, sicca syndrome, or Kayser-Fleischer rings. Primary biliary cirrhosis develops over time and might eventually lead the liver to stop functioning completely.
 
Some of the major players operating in the primary biliary cholangitis market are:
 
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Ireland)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (U.S.)
  • Allergan (Ireland)
  • AstraZeneca (U.K.)
  • Johnson & Johnson Private Limited (U.S.)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Bristol-Myers Squibb Company (U.S.)
  • Bayer AG (Germany)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Dr. Reddy’s Laboratories Ltd. (India)
  • Gilead Sciences, Inc. (U.S.)
  • Amgen Inc. (U.S.)
  • Eli Lilly and Company (U.S.)
  • AbbVie Inc. (U.S.)
  • Lupin (India)
  • Allergan (Ireland)
 
Global Primary Biliary Cholangitis Market Scope:
 
Global primary biliary cholangitis market is segmented on the basis of treatment type, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
 
Treatment Type
  • Liver Transplantation
  • Drug Therapy
  • Ursodeoxycholic acid (UDCA)
  • Obeticholic acid
  • Fibrates
  • Budesonide
  • Others
 
Diagnosis
  • Imaging Tests
  • Magnetic resonance elastography (MRE)
  • Magnetic resonance cholangiopancreatography (MRCP)
  • Ultrasound
  • FibroScan
  • Blood Tests
  • Cholesterol test
  • Antibody tests
  • Liver tests
  • Others
 
Route of Administration
  • Oral
  • Parenteral
  • Others
 
End-Users
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others
 
Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
 
 
Table of Content:
Part 01: Executive Summary
Part 02: Scope of the Report
Part 03: Primary Biliary Cholangitis Market Landscape
Part 04: Primary Biliary Cholangitis Market Sizing
Part 05: Primary Biliary Cholangitis Market Segmentation By Product
Part 06: Five Forces Analysis
Part 07: Customer Landscape
Part 08: Geographic Landscape
Part 09: Decision Framework
Part 10: Drivers and Challenges
Part 11: Market Trends
Part 12: Vendor Landscape
Part 13: Vendor Analysis
 
 
Browse Trending Reports:
 
About Data Bridge Market Research:
 
An absolute way to predict what the future holds is to understand the current trend! Data Bridge Market Research presented itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are committed to uncovering the best market opportunities and nurturing effective information for your business to thrive in the marketplace. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is a set of pure wisdom and experience that was formulated and framed in 2015 in Pune.
 
Data Bridge Market Research has more than 500 analysts working in different industries. We have served more than 40% of the Fortune 500 companies globally and have a network of more than 5,000 clients worldwide. Data Bridge is an expert in creating satisfied customers who trust our services and trust our hard work with certainty. We are pleased with our glorious 99.9% customer satisfaction rating.
 
Contact Us: -
Data Bridge Market Research
US: +1 888 387 2818
United Kingdom: +44 208 089 1725
Hong Kong: +852 8192 7475